Thermo Fisher to Manufacture Arcturus' Phase 3 Cystic Fibrosis Drug ARCT-032
ARCT sits 24% above its 52-week low of $5.85.
Summary
Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its Phase 3 cystic fibrosis drug candidate, ARCT-032. Thermo Fisher will provide manufacturing and clinical services for the program and receive exclusive commercial manufacturing rights. This partnership is a significant positive development, especially following Arcturus' recent Q1 2026 report which showed a 93% drop in revenue and a near-doubling of net loss. An 8-K filed later today confirms this partnership involves up to $80 million in manufacturing and clinical services, de-risking the ARCT-032 program and securing critical operational capabilities.
At the time of this announcement, ARCT was trading at $7.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.8M. The 52-week trading range was $5.85 to $24.17. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.